| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Thomas John Dietz | Director | 2025-12-26 | 35,000 | $1.20 | $42.00kSell |
| Christopher Mirabelli | Director | 2025-11-17 | 261,840 | $3.14 | $822.18kSell |
| Christopher Mirabelli | Director | 2025-11-17 | 414,479 | $3.14 | $1.30MSell |
| Douglas E. Onsi | CEOCFOPres.GCTreas.Sec. | 2025-11-17 | 261,840 | $3.14 | $822.18kSell |
| Douglas E. Onsi | CEOCFOPres.GCTreas.Sec. | 2025-11-17 | 414,479 | $3.14 | $1.30MSell |
| James H. Cavanaugh | Director | 2025-11-17 | 261,840 | $3.14 | $822.18kSell |
| Christopher Mirabelli | Chairman of the Board | 2025-03-28 | 6,672 | $0.32 | $2.12kSell |
| Christine Granfield | VP Head of Reg AffairsQual | 2025-03-28 | 6,604 | $0.32 | $2.09kSell |
| Augustine Lawlor | Chief Operating Officer | 2025-03-28 | 7,797 | $0.32 | $2.47kSell |
| Jason Baum | Chief Scientific Officer | 2025-03-28 | 6,604 | $0.32 | $2.09kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Perceptive Advisors LLC | 14.96% | 8,476,496 | $9.83M | Insider |
| William Patrick McEvoy Iii | 14.62% | 8,283,761 | $9.61M | Insider |
| Winklevoss Capital Fund LLC | 14.62% | 8,283,761 | $9.61M | Insider |
| Beigene Ltd | 12.97% | 7,348,437 | $8.52M | Insider |
| Gilead Sciences Inc | 9.39% | 5,319,148 | $6.17M | Insider |
| Gilead Sciences Inc | 9.39% | 5,319,148 | $6.17M | Institution |
| Healthcare Ventures IX LP | 7.32% | 4,144,804 | $4.81M | Insider |
| John W. Littlechild | 4.62% | 2,618,406 | $3.04M | Insider |
| Augustine Lawlor | 3.03% | 1,718,454 | $1.99M | Insider |
| Lilly Co Eli | 2.61% | 1,479,307 | $1.72M | Insider |